Van ECK Associates Corp lowered its position in Sanofi SA (NYSE:SNY) by 2.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 277,992 shares of the company’s stock after selling 5,729 shares during the period. Van ECK Associates Corp’s holdings in Sanofi were worth $13,841,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Assetmark Inc. increased its position in shares of Sanofi by 34.4% in the 3rd quarter. Assetmark Inc. now owns 158,305 shares of the company’s stock valued at $7,882,000 after buying an additional 40,484 shares in the last quarter. ProVise Management Group LLC boosted its stake in Sanofi by 12.0% in the 3rd quarter. ProVise Management Group LLC now owns 146,188 shares of the company’s stock worth $7,279,000 after purchasing an additional 15,675 shares during the period. Renaissance Group LLC acquired a new position in Sanofi in the 3rd quarter worth $16,239,000. Pacer Advisors Inc. boosted its stake in Sanofi by 16.9% in the 3rd quarter. Pacer Advisors Inc. now owns 64,852 shares of the company’s stock worth $3,229,000 after purchasing an additional 9,396 shares during the period. Finally, Girard Partners LTD. acquired a new position in Sanofi in the 3rd quarter worth $342,000. Institutional investors and hedge funds own 9.09% of the company’s stock.
A number of equities analysts recently weighed in on SNY shares. Argus reaffirmed a “buy” rating and issued a $55.00 target price on shares of Sanofi in a research note on Friday, September 1st. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Finally, Morgan Stanley downgraded shares of Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $53.50.
WARNING: “Van ECK Associates Corp Sells 5,729 Shares of Sanofi SA (NYSE:SNY)” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://stocknewstimes.com/2017/12/06/sanofi-sny-shares-sold-by-van-eck-associates-corp.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.